Skye Bioscience provides 2026 corporate outlook

“In 2025 we generated our Phase 2a clinical data, deepened our understanding of nimacimab’s exposure-response dynamics, and built the technical foundation required to test higher doses and prepare the framework for a potential subsequent Phase 2 trial with broader clinical endpoints,” said Punit Dhillon, CEO. “In 2026, our focus and goals are straightforward: deliver additional clinical readouts from our CBeyond extension study, assess and select higher doses of nimacimab, and launch a Phase 2b study designed to evaluate multiple doses of nimacimab as a monotherapy and in combination with an incretin therapy. We believe emerging data across the obesity treatment landscape underscore the need for modalities complementary to incretin-based therapies,” added Mr. Dhillon. “We believe peripheral CB1 inhibition offers a distinctive opportunity to help achieve incremental weight loss, improve treatment tolerability and sustainability, enhance post-treatment durability, as well as offer additional metabolic and inflammatory benefits.” Skye‘s 2026 clinical program goals are designed to evaluate multiple higher doses of nimacimab, and (nitiate a Phase 2b study that supports combination development. Planned clinical milestones include: CBeyond Phase 2a 26-week extension data update and interim results expected in Q1 2026. CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up period expected in Q3 2026. Phase 2b plan will be finalized and aligned with regulators, including completion of a Type C meeting in Q1 2026, with initiation of the adaptive design Phase 2b clinical trial expected in Q3 2026.